{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:02:29Z","timestamp":1791388949065,"version":"4.3.3"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"This study was sponsored by Sanofi"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Metabolism Res"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The effect of lixisenatide\u2014a prandial once\u2010daily glucagon\u2010like peptide\u20101 receptor agonist\u2014on glycaemic control in patients with inadequately controlled type 2 diabetes mellitus (T2DM), stratified by baseline \u03b2\u2010cell function, was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The 24\u2010week GetGoal\u2010M, \u2010P and \u2010S trials evaluated the efficacy and safety of lixisenatide in combination with oral antidiabetic agents. This post hoc analysis used data from patients receiving lixisenatide in these trials, divided into matched cohorts by propensity scoring, and stratified according to baseline homeostasis model assessment of \u03b2\u2010cell function (HOMA\u2010\u03b2) index levels, high HOMA\u2010\u03b2:\u00a0&gt;\u00a0median HOMA\u2010\u03b2 (28.49%); low HOMA\u2010\u03b2:\u00a0\u2264\u00a0median.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The matched \u201clow\u201d and \u201chigh\u201d HOMA\u2010\u03b2 index cohorts (N\u00a0=\u00a0546 patients) had comparable baseline parameters. Mean change from baseline in glycated haemoglobin (HbA<jats:sub>1c<\/jats:sub>) was \u22120.85% and \u22120.94% for low and high HOMA\u2010\u03b2 cohorts, respectively (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.2607). Reductions from baseline in fasting plasma glucose (FPG; \u22120.77 vs \u22121.04\u00a0mmol\/L; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.1496) and postprandial plasma glucose (PPG; \u22125.82 vs \u22125.61\u00a0mmol\/L; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.7511) were similar in the low versus high HOMA\u2010\u03b2 index cohorts. Reduction in body weight was significantly greater in the low versus high HOMA\u2010\u03b2 index cohort (\u20132.06 vs \u20131.13\u00a0kg, respectively; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.0006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In patients with T2DM, lixisenatide was associated with reduction in HbA<jats:sub>1c<\/jats:sub> and improvements in both FPG and PPG, regardless of \u03b2\u2010cell function, indicating that lixisenatide is effective in reducing hyperglycaemia, even in patients with more advanced stages of T2DM and poor residual \u03b2\u2010cell function.<\/jats:p><\/jats:sec>","DOI":"10.1002\/dmrr.2897","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T05:22:39Z","timestamp":1489728159000},"source":"Crossref","is-referenced-by-count":16,"title":["Lixisenatide as add\u2010on treatment among patients with different \u03b2\u2010cell function levels as assessed by HOMA\u2010\u03b2 index"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-1005","authenticated-orcid":false,"given":"Riccardo C.","family":"Bonadonna","sequence":"first","affiliation":[{"name":"University of Parma and Azienda Ospedaliero\u2010Universitaria di Parma  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Blonde","sequence":"additional","affiliation":[{"name":"Frank Riddick Diabetes Institute Department of Endocrinology, Ochsner Medical Center  New Orleans LA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Antsiferov","sequence":"additional","affiliation":[{"name":"Moscow Department of Health Care  Moscow Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Berria","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gourdy","sequence":"additional","affiliation":[{"name":"Diabetology Department Toulouse University Hospital  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mensud","family":"Hatunic","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Mater Misericordiae University Hospital  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanathan","family":"Mohan","sequence":"additional","affiliation":[{"name":"Madras Diabetes Research Foundation &amp; Dr Mohan's Diabetes Specialities Centre  Chennai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1444-0938.2005.tb06686.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70005-4"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2013.06.016"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1987.tb00821.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.881"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0632"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00969.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-S011"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP13176.CS"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"issue":"1","key":"e_1_2_9_13_1","first-page":"88","article-title":"Guidelines on diabetes, pre\u2010diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)","volume":"28","author":"Ryden L","year":"2007","journal-title":"Eur Heart J"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01663.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2006"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1935"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2462"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01618.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2014.01.012"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12076"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1984"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12121"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2541"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2013.04.001"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00354.2013"},{"issue":"5","key":"e_1_2_9_28_1","first-page":"E981","article-title":"Glucagon\u2010like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck MA","year":"1997","journal-title":"Am J Physiol"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.9.1779"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00403285"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.3.295"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01218.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.44.9.1121"},{"issue":"4","key":"e_1_2_9_35_1","first-page":"243","article-title":"The interrelationship between insulin secretion and action in type 2 diabetes mellitus with different degrees of obesity: evidence supporting central obesity","volume":"16","author":"Duman BS","year":"2003","journal-title":"Diabetes Nutr Metab"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2008"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(81)90579-9"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111542"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12147"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002348"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2036"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.111625"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s230"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12196"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00638.x"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.11.1249"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2011.05.005"},{"issue":"2","key":"e_1_2_9_48_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/dc15-0258","article-title":"Markers of beta\u2010cell failure predict poor glycemic response to GLP\u20101 receptor agonist therapy in type 2 diabetes","volume":"39","author":"Jones AG","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1487"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(91)90065-5"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"}],"container-title":["Diabetes\/Metabolism Research and Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdmrr.2897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.2897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T08:57:00Z","timestamp":1696582620000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dmrr.2897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1002\/dmrr.2897"],"URL":"https:\/\/doi.org\/10.1002\/dmrr.2897","archive":["Portico"],"relation":{},"ISSN":["1520-7552","1520-7560"],"issn-type":[{"value":"1520-7552","type":"print"},{"value":"1520-7560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]},"article-number":"e2897"}}